¼¼°èÀÇ ´ë»çüÇÐ ½ÃÀå
Metabolomics
»óǰÄÚµå : 1646768
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 415 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,263,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,789,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ´ë»çüÇÐ ½ÃÀåÀº 2030³â±îÁö 71¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 33¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ´ë»çüÇÐ ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 11.6%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 71¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÀûÀÀÁõÀº CAGR 13.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 36¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½ÉÇ÷°ü°è Áúȯ ÀûÀÀÁõ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 10.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 13¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 14.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ´ë»çüÇÐ ½ÃÀåÀº 2023³â¿¡ 13¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2023-2030³â CAGR 14.0%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â 6¾ï 8,720¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 9.5%¿Í 11.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 10.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ´ë»çüÇÐ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

´ë»çüÇÐÀº ¾î¶»°Ô »ý¹°ÇÐ ¿¬±¸ÀÇ »õ·Î¿î ÁöÆòÀ» ¿­ °ÍÀΰ¡?

´ë»çüÇÐÀº »ý¹°ÇÐÀû ½Ã½ºÅÛ¿¡¼­ ´ë»ç¹°Áú¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ¿¬±¸·Î, ¿¬±¸ÀÚµéÀÌ ¼¼Æ÷ °úÁ¤, Áúº´ ¸ÞÄ¿´ÏÁò, Ä¡·áÀû °³ÀÔÀ» ÀÌÇØÇÏ´Â ¹æ½Ä¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ ÃÖ÷´Ü ºÐ¾ß´Â ¼¼Æ÷, Á¶Á÷, »ýü¾× ³»ÀÇ ¼ÒºÐÀÚ¸¦ ºÐ¼®ÇÏ¿© °Ç°­°ú Áúº´À» Áö¹èÇÏ´Â »ýÈ­ÇÐÀû °æ·Î¿¡ ´ëÇÑ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù. ´ë»çüÇÐÀÇ ºÎ»óÀ¸·Î °úÇÐÀÚµéÀº Áúº´ÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¹ß°ßÇϰí, ¾àÈ¿¸¦ ¸ð´ÏÅ͸µÇϸç, ¾Ï, ½ÉÇ÷°ü Áúȯ, ´ë»ç¼º Áúȯ µî ´Ù¾çÇÑ Áõ»ó¿¡ ´ëÇÑ ¸ÂÃã Ä¡·á¸¦ ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Áú·®ºÐ¼®(MS), ÇÙÀÚ±â°ø¸í(NMR) µîÀÇ Ã·´Ü ºÐ¼®±â¼úÀº º¹ÀâÇÑ ´ë»ç»ê¹° ÇÁ·ÎÆÄÀÏÀÇ Á¤È®ÇÑ °ËÃâ°ú Á¤·®À» °¡´ÉÇÏ°Ô ÇÏ¿© ´ë»çü ¿¬±¸ÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¿ä±¸°¡ °è¼Ó Áõ°¡ÇÏ´Â °¡¿îµ¥, ´ë»çüÇÐÀº Çö´ë »ýÀÇÇÐ ¿¬±¸¿¡ ¾ø¾î¼­´Â ¾È µÉ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Á¦¾à ¹× ÇコÄÉ¾î ºÎ¹®ÀÌ ´ë»çüÇп¡ ÅõÀÚÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Á¦¾à ¹× ÇコÄÉ¾î ºÐ¾ß´Â ´ë»çüÇÐÀ» Ȱ¿ëÇÏ¿© ½Å¾à°³¹ßÀ» °¡¼ÓÈ­Çϰí ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. Áúº´¿¡ ƯȭµÈ ´ë»ç ½Ã±×´Ïó¸¦ ÆÄ¾ÇÇÔÀ¸·Î½á ¿¬±¸ÀÚµéÀº Ç¥Àû Ä¡·á¹ýÀ» °³¹ßÇϰí ÀÓ»ó½ÃÇèÀÇ ¼º°ø·üÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀǾàǰ °³¹ß¿¡¼­ ´ë»çüÇÐÀº ÀáÀçÀû ¾à¹° Èĺ¸¹°ÁúÀÇ ½ºÅ©¸®´×À» ¿ëÀÌÇÏ°Ô Çϰí, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸ鼭 È¿´ÉÀ» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ ±â¼úÀº ¿µ¾ç °úÇÐ ºÐ¾ß¿¡¼­µµ ½ÄÀÌ ÁßÀç¿Í ´ë»ç °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡Çϱâ À§ÇØ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó ½ÇÇè½Ç¿¡¼­´Â Áø´Ü ¸ñÀûÀ¸·Î ´ë»çüÇÐÀ» äÅÃÇÏ´Â °÷ÀÌ Á¡Á¡ ´õ ¸¹¾ÆÁö°í ÀÖÀ¸¸ç, º¸´Ù Á¤È®Çϰí Á¾ÇÕÀûÀÎ Áúº´ Æò°¡¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ °³º° ȯÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸Â´Â Ä¡·á¸¦ ÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ´ë»çüÇп¡ ´ëÇÑ ÅõÀÚ°¡ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿äÀÇ ±ÞÁõÀº Çаè, Á¦¾à»ç, Áø´Ü¾÷ü °£ÀÇ Çõ½Å°ú Çù·ÂÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀÌ ´ë»çüÇÐÀÇ »óȲÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ´ë»çü ºÐ¼®ÀÇ ÇØ»óµµ, Á¤È®µµ, ¼Óµµ¸¦ Çâ»ó½ÃŰ´Â ´ë»çü ºÐ¼®ÀÇ ÇÙ½ÉÀÔ´Ï´Ù. ÇÏÀ̽º·çDz Áú·®ºÐ¼®°ú Å©·Î¸¶Åä±×·¡ÇÇ ±â¼úÀÇ Çõ½ÅÀ¸·Î ¼öõ °³ÀÇ ´ë»ç¹°ÁúÀ» µ¿½Ã¿¡ °ËÃâÇÒ ¼ö ÀÖ°Ô µÇ¾î »ýü ½Ã½ºÅÛÀÇ Àüü»óÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º¿Í ¸Ó½Å·¯´×Àº ¿¬±¸ÀÚµéÀÌ ´ë±Ô¸ð µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®Çϰí, ÆÐÅÏÀ» ½Äº°Çϰí, º¹ÀâÇÑ ´ë»çü ÇÁ·ÎÆÄÀÏ¿¡¼­ ÀÇ¹Ì ÀÖ´Â ÀλçÀÌÆ®À» µµÃâÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ´ë»çüÇп¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ´ë»çüÇÐ, À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, Àü»çüÇÐÀ» °áÇÕÇÑ ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÇ ÅëÇÕÀº ¿¬±¸ ¹üÀ§¸¦ È®ÀåÇÏ°í »ý¹°ÇÐÀû º¹À⼺ÀÇ »õ·Î¿î ÃþÀ» ¹àÇô³»°í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû°ú ¿ÀÇ ¾×¼¼½º µ¥ÀÌÅͺ£À̽º´Â Àü ¼¼°è °øµ¿ ¿¬±¸¸¦ ÃËÁøÇϰí, ¸ÞŸº¼·Ò µ¥ÀÌÅÍ¿¡ ´ëÇÑ Á¢±ÙÀ» ¿ëÀÌÇÏ°Ô Çϸç, ´ÙÇÐÁ¦Àû ¿¬±¸¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú ¹ßÀüÀº ½Å¾à °³¹ß¿¡¼­ ȯ°æ ¸ð´ÏÅ͸µ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ ´ë»çüÇÐÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí Çö´ë °úÇÐÀÇ Ãʼ®À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

´ë»çüÇÐ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

´ë»çüÇÐ ½ÃÀåÀÇ ¼ºÀåÀº °í±Þ Áø´Ü Åø¿Í ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â ¸¸¼ºÁúȯ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ë»çüÇÐÀº °³ÀÎÀÇ °Ç°­ ÇÁ·ÎÆÄÀϰú Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ µ¶º¸ÀûÀÎ ÀλçÀÌÆ®À» Á¦°øÇϹǷΠÁ¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Áú·®ºÐ¼®, NMR, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º µîÀÇ ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇØ ´ë»çü ºÐ¼®ÀÌ º¸´Ù È¿À²ÀûÀ̰í Á¤È®Çϸç Á¢±Ù¼ºÀÌ ³ô¾ÆÁ® Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÇ ÅõÀÚ¸¦ À̲ø¾î³»°í ÀÖ½À´Ï´Ù. ¸ÖƼ¿À¹Í½º ¿¬±¸ÀÇ È®´ë´Â »ý¹°ÇÐÀû ½Ã½ºÅÛ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀÌÇØ¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ´ë»çüÇÐÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇコÄɾ¼­ ¿µ¾ç°ú ´ë»çÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó °³ÀÎ ¸ÂÃãÇü ¿µ¾ç ¹× À£´Ï½º ÇÁ·Î±×·¥¿¡ ´ë»çüÇÐÀÌ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. Çаè, »ê¾÷°è, ±ÔÁ¦±â°ü °£ÀÇ Çù·ÂÀû ³ë·ÂÀº ÀÌ ºÐ¾ßÀÇ Çõ½Å°ú Ç¥ÁØÈ­¸¦ ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº ´ë»çüÇÐÀÌ ÇコÄɾî¿Í »ý¹° ÀÇÇÐ ¿¬±¸ÀÇ ¹Ì·¡¸¦ ¹Ù²Ü ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÀûÀÀÁõ(¾ÏÀûÀÀÁõ, ½ÉÇ÷°üÁúȯ ÀûÀÀÁõ, ½Å°æÁúȯ ÀûÀÀÁõ, ¼±Ãµ¼º ´ë»çÀÌ»ó ÀûÀÀÁõ, ±âŸ ÀûÀÀÁõ), ¿ëµµ(¹ÙÀÌ¿À¸¶Ä¿ Ž»ö ¿ëµµ, Drug Discovery ¿ëµµ, µ¶¼º ½ÃÇè ¿ëµµ, ¿µ¾çÀ¯ÀüüÇÐ ¿ëµµ, ¸ÂÃãÇü ÀÇ·á ¿ëµµ, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(Çмú¡¤¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷ ÃÖÁ¾ ¿ëµµ, ¼öŹ ¿¬±¸±â°ü ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 63»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Metabolomics Market to Reach US$7.1 Billion by 2030

The global market for Metabolomics estimated at US$3.3 Billion in the year 2023, is expected to reach US$7.1 Billion by 2030, growing at a CAGR of 11.6% over the analysis period 2023-2030. Cancer Indication, one of the segments analyzed in the report, is expected to record a 13.0% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Cardiovascular Disorder Indication segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 14.0% CAGR

The Metabolomics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$687.2 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.5% and 11.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Metabolomics Market – Key Trends & Drivers Summarized

How Is Metabolomics Unlocking New Frontiers in Biological Research?

Metabolomics, the comprehensive study of metabolites in biological systems, is revolutionizing the way researchers understand cellular processes, disease mechanisms, and therapeutic interventions. This cutting-edge field provides insights into the biochemical pathways that govern health and disease by analyzing small molecules within cells, tissues, or biofluids. The rise of metabolomics has enabled scientists to uncover biomarkers for early disease detection, monitor drug efficacy, and personalize treatments for various conditions, including cancer, cardiovascular diseases, and metabolic disorders. Advanced analytical technologies, such as mass spectrometry (MS) and nuclear magnetic resonance (NMR), are central to metabolomics research, allowing for the accurate detection and quantification of complex metabolite profiles. As the demand for precision medicine continues to grow, metabolomics is becoming an indispensable tool in modern biomedical research.

Why Are Pharmaceutical and Healthcare Sectors Investing in Metabolomics?

The pharmaceutical and healthcare sectors are leveraging metabolomics to accelerate drug discovery and enhance patient outcomes. By identifying disease-specific metabolic signatures, researchers can develop targeted therapies and improve the success rates of clinical trials. In drug development, metabolomics facilitates the screening of potential drug candidates, optimizing efficacy while minimizing adverse effects. The technology is also gaining traction in nutritional science, where it is used to evaluate dietary interventions and their impact on metabolic health. Clinical laboratories are increasingly adopting metabolomics for diagnostic purposes, offering more accurate and comprehensive assessments of diseases. Furthermore, the growing emphasis on personalized medicine is driving investments in metabolomics, enabling healthcare providers to tailor treatments to individual patient profiles. This surge in demand is fostering innovation and collaboration between academic institutions, pharmaceutical companies, and diagnostic firms.

How Are Technological Advances Shaping the Metabolomics Landscape?

Technological advancements are at the heart of metabolomics, enhancing the resolution, accuracy, and speed of metabolite analysis. Innovations in high-throughput mass spectrometry and chromatography techniques are enabling the simultaneous detection of thousands of metabolites, providing a holistic view of biological systems. Bioinformatics and machine learning are playing a pivotal role in metabolomics, allowing researchers to analyze large datasets, identify patterns, and derive meaningful insights from complex metabolomic profiles. The integration of multi-omics approaches, combining metabolomics with genomics, proteomics, and transcriptomics, is expanding the scope of research and uncovering new layers of biological complexity. Cloud-based platforms and open-access databases are facilitating global collaboration, making metabolomic data more accessible and enabling cross-disciplinary research. These technological advancements are driving the adoption of metabolomics in diverse fields, from drug development to environmental monitoring, cementing its position as a cornerstone of modern science.

What Factors Are Driving Growth in the Metabolomics Market?

The growth in the metabolomics market is driven by several factors, including the increasing prevalence of chronic diseases, which necessitate advanced diagnostic tools and personalized treatment approaches. The rising demand for precision medicine is a key driver, as metabolomics offers unparalleled insights into individual health profiles and therapeutic responses. Technological innovations, such as advancements in mass spectrometry, NMR, and bioinformatics, are making metabolomic analysis more efficient, accurate, and accessible, attracting investments from pharmaceutical and biotechnology companies. The expansion of multi-omics research is also propelling the adoption of metabolomics, as it enables a comprehensive understanding of biological systems. Furthermore, the growing awareness of the role of nutrition and metabolism in health management is driving the application of metabolomics in personalized nutrition and wellness programs. Collaborative efforts between academia, industry, and regulatory bodies are fostering innovation and standardization in the field, further accelerating market growth. These factors highlight the transformative potential of metabolomics in shaping the future of healthcare and biomedical research.

SCOPE OF STUDY:

The report analyzes the Metabolomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Cancer Indication, Cardiovascular Disorder Indication, Neurological Disorder Indication, Inborn Errors of Metabolism Indication, Other Indications); Application (Biomarker Discovery Application, Drug Discovery Application, Toxicology Testing Application, Nutrigenomics Application, Personalized Medicine Application, Other Applications); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 63 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â